Madison-based Stratatech has submitted an application to the Food and Drug Administration for StrataGraft, a regenerative skin tissue to treat burns, according to a company release.
The “rolling submission” of the application for StrataGraft, a tissue product using human cells derived from skin, started in April and is now complete. Stratatech was purchased by Mallinckrodt Pharmaceuticals in 2016.
